Omega-3 intake link to reduced heart risk — Clinical trial meta-analysis

Organisation: Position: Deadline Date: Location:

A Mayo Clinic  meta-analysis of 40 clinical trials provides evidence for consuming more EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) omega-3 fats, improving cardiovascular disease (CVD) and heart attack risk.

The study, published in Mayo Clinic Proceedings, found that EPA+DHA supplementation is associated with a statistically significant reduced risk of: fatal myocardial infarction (35%); myocardial infarction (13%); CHD events (10%); and CHD mortality (9%). The study was commissioned by the Global Organisation for EPA and DHA Omega-3s.

The research concludes that EPA and DHA omega-3 intake is associated with reduced risk of coronary heart disease (CHD) events, the cause of 7.4m deaths globally each year, and reduced risk of myocardial infarction (heart attack), including fatal heart attack.

“The study supports the notion that EPA and DHA intake contributes to cardioprotection, and that whatever patients are getting through the diet, they likely need more,” said Dr Carl “Chip” Lavie, a cardiologist at Ochsner Health in New Orleans, and one of the study authors.

Cardiovascular benefits appear to increase with dosage. The researchers found that adding an extra 1000 mg of EPA and DHA per day decreased the risk of cardiovascular disease and heart attack even more: risk of cardiovascular disease events decreased by 5.8% and risk for heart attack decreased by 9.0%. The study looked at dosages of up to 5500 mg/day.

This research corroborates the results of an earlier meta-analysis from Harvard School of Public Health, published in fall 2019, that looked at EPA and DHA dosage using the 13 largest clinical studies. This new paper encompasses more than triple the number of studies, which represents the totality of the evidence to date and includes more than 135,000 study participants.

“When separate analyses arrive at similar results, that’s not only validating; it also underscores the science base needed to inform future intake recommendations,” said co-author Dr Aldo Bernasconi, vice president of data science for the Global Organisation for EPA and DHA Omega-3s (GOED), which commissioned the study. “Because this paper included more studies and all dosages, the estimates for a dose-response are more precise and the conclusions stronger.”

EPA and DHA omega-3s are long-chain, marine-based fatty acids. Eating fish, particularly fatty fish such as salmon, anchovies and sardines, is the optimal way to get EPA and DHA omega-3s, since fish also provides other beneficial nutrients. However, most people around the world eat much less than the amount of fish recommended, so supplementing with omega-3s helps close the gap.

“People should consider the benefits of omega-3 supplements, at doses of 1000 to 2000 mg per day – far higher than what is typical, even among people who regularly eat fish,” added Lavie. “Given the safety and diminished potential for interaction with other medications, the positive results of this study strongly suggest omega-3 supplements are a relatively low-cost, high impact way to improve heart health with few associated risks and should be considered as part of a standard preventive treatment for most patients with cardiovascular diseases and those recovering from myocardial infarction.”

Abstract
Objectives: To quantify the effect of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids on cardiovascular disease (CVD) prevention and the effect of dosage.
Methods: This study is designed as a random effects meta-analysis and meta-regression of randomized control trials with EPA/DHA supplementation. This is an update and expanded analysis of a previously published meta-analysis which covers all randomized control trials with EPA/DHA interventions and cardiovascular outcomes published before August 2019. The outcomes included are myocardial infarction (MI), coronary heart disease (CHD) events, CVD events (a composite of MI, angina, stroke, heart failure, peripheral arterial disease, sudden death, and non-scheduled cardiovascular surgical interventions), CHD mortality and fatal MI. The strength of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation framework.
Results: A total of 40 studies with a combined 135,267 participants were included. Supplementation was associated with reduced risk of MI (relative risk [RR], 0.87; 95% CI, 0.80 to 0.96), high certainty number needed to treat (NNT) of 272; CHD events (RR, 0.90; 95% CI, 0.84 to 0.97), high certainty NNT of 192; fatal MI (RR, 0.65; 95% CI, 0.46 to 0.91]), moderate certainty NNT = 128; and CHD mortality (RR, 0.91; 95% CI, 0.85 to 0.98), low certainty NNT = 431, but not CVD events (RR, 0.95; 95% CI, 0.90 to 1.00). The effect is dose dependent for CVD events and MI.
Conclusion: Cardiovascular disease remains the leading cause of death worldwide. Supplementation with EPA and DHA is an effective lifestyle strategy for CVD prevention, and the protective effect probably increases with dosage.

Authors
Aldo A Bernasconi, Michelle M Wiest, Carl J Lavie, Richard V Milani, Jari A Laukkanen

 

Elsevier material

 

Mayo Clinic Proceedings abstract

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.